Targetrin LGD1069 oral RXR-selective retinoid compound data

University researchers reported on an ongoing Phase I/II dose escalation trial of Targetrin in patients with non-small cell lung cancer. In 8 of 15 patients, up to 650 mg/m2/day of compound resulted in disease stabilization for a mean of 132 days. No objective tumor regression was observed. ...